



US 20210261538A1

(19) **United States**(12) **Patent Application Publication****Jin et al.**(10) **Pub. No.: US 2021/0261538 A1**(43) **Pub. Date: Aug. 26, 2021**

(54) **PROTEIN ARGININE
METHYLTRANSFERASE 5 (PRMT5)
DEGRADATION / DISRUPTION
COMPOUNDS AND METHODS OF USE**

Related U.S. Application Data

(60) Provisional application No. 62/634,039, filed on Feb. 22, 2018.

(71) Applicant: **ICAHN SCHOOL OF MEDICINE
AT MOUNT SINAI, New York, NY
(US)**

Publication Classification

(51) **Int. Cl.**
C07D 417/14 (2006.01)
C07D 401/14 (2006.01)
(52) **U.S. Cl.**
CPC **C07D 417/14** (2013.01); **C07D 401/14**
(2013.01)

(72) Inventors: **Jian Jin, New York, NY (US); Jing
Liu, Oradell, NJ (US); Yudao Shen,
New York, NY (US); Ernesto
Guccione, New York, NY (US); Martin
Walsh, New York, NY (US);
Almudena Bosch, New York, NY (US);
Megan Schwarz, New York, NY (US)**

(57) **ABSTRACT**

Disclosed are protein arginine methyltransferase 5 (PRMT5) degradation/disruption compounds including a PRMT5 ligand, a degradation/disruption tag and a linker, and methods for use of such compounds in the treatment of PRMT5-mediated diseases. The PRMT5 degraders disclosed herein offer a novel mechanism for treating PRMT5-mediated diseases compared to small molecule inhibitors of PRMT5 activity.

(21) Appl. No.: **16/970,305**

(22) PCT Filed: **Feb. 22, 2019**

(86) PCT No.: **PCT/US2019/019123**

§ 371 (c)(1),

(2) Date: **Aug. 14, 2020**

